Novo Nordisk A/S
Latest Novo Nordisk A/S News and Updates
Company & Industry OverviewsGlaxoSmithKline’s Segment Performances in 1Q17
GlaxoSmithKline (GSK) reported a 19.0% rise in 1Q17 revenues to ~7.4 billion pounds, driven by an operational rise of 5.0% and a favorable currency impact of 14.0%. Company & Industry OverviewsHow AstraZeneca’s Growth Platforms Performed in 1Q17
A few of the segments AstraZeneca identifies as growth platforms include Respiratory products, new Cardiovascular and Metabolic Diseases products, and new Oncology products. Company & Industry OverviewsSanofi’s Generics and Consumer Healthcare Business in 1Q17
Sanofi’s (SNY) Generics business contributes ~5% to the group’s total revenues. Company & Industry OverviewsPerformance of Sanofi Genzyme in 1Q17
Sanofi (SNY) reported growth of over 15% at constant exchange rates in its 1Q17 revenues from Genzyme. Company & Industry OverviewsGardasil and Merck’s Vaccines Business in 1Q17
Gardasil is Merck’s (MRK) leading vaccine franchise. Total sales for Gardasil in 1Q17 were $532.0 million, a ~41.0% rise over $378.0 million in 1Q16. Earnings ReportEli Lilly’s 1Q17 Estimates for Humalog, Other Endocrine Products
Eli Lilly’s (LLY) human pharmaceutical segment contributes ~85.0% to Lilly’s total revenues. Company & Industry OverviewsWhat Happened to Sanofi’s Valuation after 4Q16?
On February 16, 2017, Sanofi was trading at a forward PE multiple of ~13.9x, as compared to the industry average of 15.7x. Earnings ReportHow Tresiba Helps Novo Achieve Its Growth Targets
During the first nine months of 2016, Novo’s (NVO) new generation portfolio garnered 2.8 billion Danish kroner. Earnings ReportVictoza Dominates Global GLP-1 Class
Novo’s (NVO) Victoza is a glucagon-like peptide-1 (or GLP-1) therapy for type 2 Diabetes patients. Earnings ReportUS Still the Largest Market for Novo Nordisk
During 3Q16, Novo’s sales in the US rose 2% in local currency terms to 14.2 billion Danish kroner. Earnings ReportHow Much Is the Return Opportunity for Novo Nordisk in 3Q16?
A Bloomberg survey of two brokerage houses on October 24, 2016, reflected a 50% “buy” rating and a 50% “hold” rating for the stock. Company & Industry OverviewsWill Novo Nordisk’s Core Capabilities Be Enough to Differentiate Its Research Pipeline?
Novo Nordisk’s search for new molecules through partnerships and other alliances has proven instrumental in strengthening its R&D pipeline. Company & Industry OverviewsNovo Nordisk Expects to Witness Strong Growth from New Product Launches
In addition to its robust drug portfolio, Novo Nordisk boasts a strong research pipeline in the diabetes, hemophilia, obesity, and growth disorder segments. Company & Industry OverviewsNovo Nordisk Is Expected to See Strong Growth in Insulin Segment
Insulin sales volumes sold across the world have grown at a compounded average growth rate (or CAGR) of 4.1% from May 2011 to May 2016. Company & Industry OverviewsWill Sanofi See More Growth from Its Blockbuster Insulin Drug?
Sanofi’s diabetes franchise includes Lantus, Toujeo, Amaryl, and Apidra. Lantus, a glargine insulin, contributed 17% of total revenues in fiscal 2015. Company & Industry Overviews2016’s Estimated Product Launches: LixiLan, Sarilumab, Lixisenatide
LixiLan indicated for type 2 diabetes is a combination of Lantus and lixisenatide. Lantus is Sanofi’s most frequently prescribed diabetes drug. Company & Industry OverviewsWhy Are Revenues from Pfizer’s Rare Disease Portfolio Falling?
BeneFIX, the major contributor to Pfizer’s (PFE) Rare Disease portfolio, is indicated for hemophilia B. During the first six months, the drug earned $367 million. Company & Industry OverviewsBehind Sanofi’s Diabetes and Cardiovascular Performance in 2Q16
Sanofi’s Diabetes and Cardiovascular revenues declined by ~2% at constant exchange rates to 1.96 billion euros (about $2.21 billion) in 2Q16. Earnings ReportHow Did Novo Nordisk Perform across Geographies in 1H16?
As of May 2016, Novo Nordisk (NVO) held a 46% share of the global total insulin market. Macroeconomic AnalysisScandinavian Indexes Rally as Inflation Rises in Norway and Denmark
The Scandinavian indexes were trading on a higher note towards the end of the day on July 11 following higher inflation numbers in Scandinavian countries. Company & Industry OverviewsWhat Are Novartis’s Key Business Segments?
Novartis’s new structure includes only three business segments: pharmaceuticals, Alcon, and Sandoz. Earnings ReportNovo’s Geographical Sales Split in 1Q16
Novo Nordisk’s US sales rose annually by 12% in local currency in 1Q16. North America remained its major market, constituting ~50% of its total revenue. Company & Industry OverviewsA Look at Baxalta’s Product Segments
Baxalta’s (BXLT) product portfolio can be divided into three parts: hematology, immunology, and oncology. Company & Industry OverviewsNovo Nordisk’s Innovative Research and Development Pipeline
Novo Nordisk’s research and development pipeline includes three late-stage insulin studies of faster-acting insulin aspart, semaglutide, and LATIN T1D. Company & Industry OverviewsNovo Nordisk: Core Capabilities Differentiate It from Competition
Novo Nordisk has developed certain core capabilities that differentiate the company from its competition. One is establishing local organizations in emerging markets and then growing organically. Company & Industry OverviewsNovo Nordisk Plans to Pursue Leadership in Hemophilia Market
Novo Nordisk is pursuing leadership in the hemophilia market with its new drugs as well as a few investigational hemophilia drugs in its late-stage research pipeline. Company & Industry OverviewsNovo Nordisk’s Business Model: An Overview
Novo Nordisk’s (NVO) business model includes a portfolio in areas such as diabetes, hemophilia, and growth hormones. In the first half of 2015, diabetes care accounted for 78.6% of its total revenues. Company & Industry OverviewsNovo Nordisk: An Investor’s Guide to a Leading Biotech Company
Novo Nordisk (NVO) is a leader in diabetes care with 90 years of experience coupled with a strong workforce of 39,700 in 75 countries around the world.